Joel Renick

Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine—a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays

Glenn Noronha, Kathy Barrett, Antonio Boccia et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 46 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Chemistry +13

Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration

Moorthy S. S. Palanki, Hideo Akiyama, Peter A. Campochiaro et al. · Journal of Medicinal Chemistry · 2008 · 44 citations · Full text

p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

Anikó M. Redman, Jeffrey S. Johnson, Robert Dally et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 44 citations · Full text

Pharmaceutical Chemistry, P38 Kinase Inhibitors, Medicine +9

Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors

Uday R. Khire, Donald Bankston, J A Barbosa et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 44 citations · Full text

Molecular Pharmacology, Biochemistry, Medicine +5

Inhibitors of ABL and the ABL-T315I Mutation

Glenn Noronha, Jianguo Cao, Chun P. Chow et al. · Current Topics in Medicinal Chemistry · 2008 · 41 citations